InvestorsHub Logo
Followers 12
Posts 616
Boards Moderated 0
Alias Born 05/06/2016

Re: ohm20 post# 78218

Wednesday, 05/27/2020 12:03:47 PM

Wednesday, May 27, 2020 12:03:47 PM

Post# of 232503
I think I’m finally up to speed here with the MoA and list of indications. Since we’re working with a CCR5 antagonist that does not disrupt normal immune function - you can add virtually every condition ending in ‘itis’ to this list. Inflammation is the cause of most, if not all age-related diseases, and since leronlimab restores immune/inflammatory homeostasis - there is a theoretical application for every inflammatory condition. A “generational drug”. Thoughts?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News